The main focus is on the plausible mechanisms by which torsinA and its activator LAP1 regulate hepatic lipid metabolism and NAFLD/NASH development (summarized in Figure 4). This evidence concerns the gene TOR1A and metabolic dysfunction-associated steatotic liver disease.